Developed by Janssen, the pharmaceutical arm of Johnson & Johnson, it is the fourth vaccine the EU has granted conditional marketing authorization, after those of BioNTech-Pfizer, Moderna, and AstraZeneca.
Johnson & Johnson’s COVID-19 vaccine was approved for emergency use on February 27. It is the first single-dose vaccine authorised in the United States.
Johnson & Johnson has prepared 4 million doses for the initial shipment and expected to ship more than 20 million doses by March, according to the company.
Around 90 percent of Israelis above the age of 60 received the COVID-19 vaccine, while only half of the people aged 16-39 have been inoculated
The discussion explored requirements for very rapid development, manufacturing, and regulatory approval of vaccines for COVID-19 variants in the EU, according to the press release.